Findings on Simultaneous Perception of Colors and the Impact of Treatment with Argus II to be Presented at EURETINA

Findings on Simultaneous Perception of Colors and the Impact of Treatment with Argus II to be Presented at EURETINA PR Newswire MILAN, September 6, 2012 MILAN, September 6, 2012 /PRNewswire/ -- The New Treatment Pathway for Retinitis Pigmentosa Second Sight Medical Products, Inc., the world's only developer and ®manufacturer of an approved retinal prosthesis for the blind, the Argus II Retinal Prosthesis System (Argus II), is featuring an extensive program of symposia, presentations and posters at the 12th EURETINA Congress from 6-9 September 2012 in Milan, Italy. Several investigators from the leading eye hospitals in Europe will present nearly a dozen talks and posters over the four day event. Argus II is the first approved treatment for severe to profound outer retinal degeneration in the European Economic Area. The largest clinical trial of a retinal prosthesis to date demonstrates that the retinal prosthesis can reliably withstand long-term implant (> 5 years) while offering a positive benefit/safety profile. Subjects demonstrated clear improvements in visual function and report using Argus II in their daily lives and have shown that the system has a positive impact in their life (as measured by the Functional Low-vision Observer Rated Assessment (FLORA™)).